[go: up one dir, main page]

MA35882B1 - Pde9 inhibitors comprising an imidazotriazinone skeleton - Google Patents

Pde9 inhibitors comprising an imidazotriazinone skeleton

Info

Publication number
MA35882B1
MA35882B1 MA37237A MA37237A MA35882B1 MA 35882 B1 MA35882 B1 MA 35882B1 MA 37237 A MA37237 A MA 37237A MA 37237 A MA37237 A MA 37237A MA 35882 B1 MA35882 B1 MA 35882B1
Authority
MA
Morocco
Prior art keywords
compound
formula
present
relates
effective amount
Prior art date
Application number
MA37237A
Other languages
French (fr)
Inventor
Niels Svenstrup
Klaus Baek Simonsen
Lars Kyhn Rasmussen
Karsten Juhl
Morten Langgård
Kate Wen
Yazhou Wang
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2013/051451 external-priority patent/WO2013110768A1/en
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of MA35882B1 publication Critical patent/MA35882B1/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La présente invention concerne des composés qui sont des inhibiteurs de l'enzyme pde9. L'invention concerne une composition pharmaceutique qui comprend une quantité thérapeutiquement efficace d'un composé de l'invention et un excipient pharmaceutiquement acceptable. La présente invention concerne également des procédés de préparation des composés de formule (i). La présente invention concerne en outre une méthode de traitement d'un sujet souffrant d'une maladie neurodégénérative, qui comprend l'administration au sujet d'une quantité thérapeutiquement efficace d'un composé de formule (i). La présente invention concerne en outre un composé de formule (i) pour une utilisation dans une méthode de traitement d'un sujet souffrant d'un trouble psychiatrique, comprenant l'administration au sujet d'une quantité thérapeutiquement efficace d'un composé de formule (i).The present invention relates to compounds which are inhibitors of the enzyme pde9. The invention relates to a pharmaceutical composition which comprises a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable excipient. The present invention also relates to processes for preparing compounds of formula (i). The present invention further relates to a method of treating a subject suffering from a neurodegenerative disease, which comprises administering to a subject a therapeutically effective amount of a compound of formula (i). The present invention further relates to a compound of formula (i) for use in a method of treating a subject suffering from a psychiatric disorder, comprising administering to a therapeutically effective amount a compound of formula (i).

MA37237A 2012-01-26 2014-07-23 Pde9 inhibitors comprising an imidazotriazinone skeleton MA35882B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2012070718 2012-01-26
PCT/EP2013/051451 WO2013110768A1 (en) 2012-01-26 2013-01-25 Pde9 inhibitors with imidazo triazinone backbone

Publications (1)

Publication Number Publication Date
MA35882B1 true MA35882B1 (en) 2014-12-01

Family

ID=53171642

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37237A MA35882B1 (en) 2012-01-26 2014-07-23 Pde9 inhibitors comprising an imidazotriazinone skeleton

Country Status (1)

Country Link
MA (1) MA35882B1 (en)

Similar Documents

Publication Publication Date Title
MA37958A1 (en) Pde9i having an imidazo pyrazinone skeleton
MA33923B1 (en) HETERAROMATIC PHENYLIMIDAZOLE DERIVATIVES AS INHIBITORS OF ENZYME PDE10A
MA51204B1 (en) Pharmaceutical forms comprising a plasma kallikrein inhibitor
EA201290518A1 (en) Derivatives of 2-aryl imidazole as inhibitors of the PDE10A enzyme
MA35404B1 (en) Compounds for the treatment of drug addiction
MY152949A (en) Novel phenylimidazole derivatives as pde10a enzyme inhibitors
UA112065C2 (en) IMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS
MA34837B1 (en) INDOLIC COMPOUNDS OR ANALOGS THEREFOR USEFUL IN THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD)
MA37405A1 (en) Heterocyclyl compounds
MA30412B1 (en) Pharmaceutical Compounds
PH12014501695B1 (en) Pde9 inhibitors with imidazo triazinone backbone
UA102693C2 (en) Phenylimidazole derivatives as pde10a enzyme inhibitors
MA32108B1 (en) Indendazole derivatives
MA31447B1 (en) NOVEL DICARBOXYLIC ACID DERIVATIVES AS S1P1 RECEPTOR AGONISTS
MA35191B1 (en) Spiro- [1,3] -oxazines and spiro- [1,4] -oxazepines as inhibitors of baec1 and / or bace2
EA201290516A1 (en) HETEROAROMATIC DERIVATIVES OF PHENYLIMIDAZOLE AS A PDE10A ENZYME INHIBITOR
WO2019007696A1 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of fibrosis
MA34308B1 (en) SUBSTITUTED TRIAZOLOPYRIDINES
MA54318B1 (en) CAPSULE FORMULATIONS
MA38679A1 (en) Cxcr7 receiver modulators
MA32061B1 (en) Triazolopyridazines as par1 inhibitors, production thereof, and use as medicaments
MA43913A (en) POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC M1 RECEPTOR
MA33166B1 (en) USE OF PYRIMIDYLAMINOBENZAMIDE DERIVATIVES FOR THE TREATMENT OF FIBROSIS
MA38307A1 (en) 4-hydroxy-2-methyl-5- (propan-2-ylidene) cyclohex-3-enecarbaldehyde for the prevention and treatment of cognitive, neurodegenerative or neuronal disease
MA35882B1 (en) Pde9 inhibitors comprising an imidazotriazinone skeleton